Eczema
peanut allergy, eczema
PEANUT ALLERGY, PEANUT ALLERGY, ECZEMA
Participants with eczema at baseline contributed disproportionately to the prevalence of peanut allergy: 0.9% (8/900) in those with no eczema versus 8.7% (78/895) in those with eczema. The effect of early introduction in these eczema subgroups is key to determining the potential impact of any early introduction strategy.The protective effect of early introduction was evident across all eczema severities with significant ITT reductions in peanut allergy prevalence in mild (85% reduction), moderate (87% reduction) and severe (67% reduction) eczema severity groups (Figure Peanut allergy prevalence by eczema severity—(A) intention‐to‐treat and (B) per‐protocol populations. Prevalence of peanut allergy in each randomized treatment group is shown by baseline eczema subgroups when data from the EAT and LEAP studies are combined in (A) ITT analysis and (B) PP analysis. Number of peanut allergy (PA) and total number of participants (